Brokers Issue Forecasts for Apellis Pharmaceuticals, Inc.’s FY2025 Earnings (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Investment analysts at Wedbush decreased their FY2025 earnings per share estimates for shares of Apellis Pharmaceuticals in a research report issued on Wednesday, April 17th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of $2.23 for the year, down from their previous forecast of $2.24. Wedbush currently has a “Neutral” rating and a $57.00 target price on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.33) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.73). The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The company’s quarterly revenue was up 545.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.50) EPS.

APLS has been the topic of a number of other research reports. Raymond James boosted their target price on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a research note on Thursday, January 11th. Needham & Company LLC reissued a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, April 9th. Jefferies Financial Group raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their target price for the company from $68.00 to $80.00 in a report on Monday, February 5th. Mizuho reissued a “neutral” rating and set a $60.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Three analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ APLS opened at $47.51 on Thursday. Apellis Pharmaceuticals has a twelve month low of $19.83 and a twelve month high of $94.75. The stock’s 50 day moving average price is $60.13 and its 200-day moving average price is $56.97. The company has a market capitalization of $5.73 billion, a PE ratio of -10.60 and a beta of 0.88. The company has a quick ratio of 2.50, a current ratio of 3.10 and a debt-to-equity ratio of 0.48.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. raised its position in Apellis Pharmaceuticals by 69.0% in the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after acquiring an additional 265 shares during the period. Future Financial Wealth Managment LLC bought a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at $29,000. Covestor Ltd raised its position in shares of Apellis Pharmaceuticals by 564.2% during the 3rd quarter. Covestor Ltd now owns 797 shares of the company’s stock valued at $30,000 after purchasing an additional 677 shares during the period. Stephens Consulting LLC bought a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $38,000. Finally, US Bancorp DE increased its holdings in Apellis Pharmaceuticals by 391.2% in the 1st quarter. US Bancorp DE now owns 1,110 shares of the company’s stock valued at $56,000 after acquiring an additional 884 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, CFO Timothy Eugene Sullivan sold 3,551 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total transaction of $230,815.00. Following the completion of the transaction, the chief financial officer now directly owns 95,675 shares of the company’s stock, valued at $6,218,875. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CFO Timothy Eugene Sullivan sold 3,551 shares of the stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $65.00, for a total value of $230,815.00. Following the completion of the transaction, the chief financial officer now directly owns 95,675 shares of the company’s stock, valued at $6,218,875. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Adam J. Townsend sold 3,413 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $65.00, for a total transaction of $221,845.00. Following the transaction, the insider now directly owns 94,507 shares of the company’s stock, valued at approximately $6,142,955. The disclosure for this sale can be found here. Insiders sold a total of 406,651 shares of company stock worth $25,130,257 over the last three months. Company insiders own 7.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).